This Week's CGT News: World's First Solid Tumor CAR T Approved in China

1

China's National Medical Products Administration approved satricabtagene autoleucel, the first CAR T-cell therapy for solid tumors.
2

Satricabtagene autoleucel targets Claudin18.2 and is approved for advanced gastric or gastroesophageal junction adenocarcinoma.
3

Approval is based on the phase 2 CT041-ST-01 trial, showing progression-free and overall survival benefits for satricabtagene autoleucel.
4

Wearable devices may help detect cytokine release syndrome earlier in CAR T-cell therapy patients, according to a pilot study.
5

A liver-targeted gene therapy showed promise in mice for treating arthrogryposis, renal dysfunction, and cholestasis syndrome.